Teva
As of the edition of 20 October 2026, Teva runs 15 drugs, 15 of them marketed; it is on route A at 0 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 15 |
| Total | 15 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Paclitaxel | none listed | 0 |
| Budesonide | Ends 2029 (exclusivity) | 5 |
| Formoterol | none listed | 2 |
| Eltrombopag | Ended 2025 (patent) | 1 |
| Trimethoprim | none listed | 0 |
| Betamethasone | none listed | 6 |
| Glatiramer acetate | none listed | 0 |
| Fremanezumab | Ends 2030 (computed from the first US licence) | 4 |
| Tetrabenazine | none listed | 1 |
| Zinc acetate anhydrous | none listed | 0 |
| Betamethasone valerate | none listed | 4 |
| Pimozide | none listed | 0 |
| Dyphylline | none listed | 0 |
| Epoetin theta | none listed | 0 |
| Meprobamate | none listed | 3 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 5 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Teva needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.